THROMBOTIC THROMBOCYTOPENIC PURPURA AFTER VACCINATION AGAINST COVID-19 - A CASE REPORT
Asian Journal of Pharmaceutical and Clinical Research
; 15(4):1-3, 2022.
Article
in English
| EMBASE | ID: covidwho-1818972
ABSTRACT
Thrombotic thrombocytopenic purpura (TTP) is a rare but fatal thrombotic microangiopathy. Circulating AntiADAMTS13 antibodies produced in response to various triggering events, such as vaccinations, autoimmune disorders, malignancy, and administration of several drugs lead to acquired TTP (aTTP). This case concerns a 26-year-old male with aTTP after receiving the second dose of the Covishield vaccine (Oxford-AstraZeneca COVID-19 vaccine, code-named AZD1222). He presented with bruises, petechia, fatigue, dyspnea, and arthralgia post-vaccination. Laboratory reports showed thrombocytopenia, hemolytic anemia, a significant ADAMTS13 deficiency, and a high level of autoantibody titer against ADAMTS13. We treated the patient with plasma exchange therapy and prednisolone, and after the treatment, he recovered.
acquired thrombotic thrombocytopenic purpura; adult; arthralgia; article; case report; clinical article; contusion; coronavirus disease 2019; drug therapy; dyspnea; fatigue; gene expression; hemolytic anemia; human; human tissue; male; petechia; plasma exchange; thrombocytopenia; thrombotic thrombocytopenic purpura; vaccination; autoantibody; endogenous compound; prednisolone; vaxzevria; von Willebrand factor cleaving proteinase
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Type of study:
Case report
Topics:
Vaccines
Language:
English
Journal:
Asian Journal of Pharmaceutical and Clinical Research
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS